Landmarks in prostate cancer screening

BJU International

Volumn 110, Issue SUPPL. 1, 2012, Pages 3-7

  Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

disease stage; prostate cancer; PSA; screening; survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVERSE OUTCOME; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; DIGITAL RECTAL EXAMINATION; FEVER; FOLLOW UP; HEMATURIA; HEMOSPERMIA; HUMAN; LUNG CANCER; METASTASIS; NEEDLE BIOPSY; OUTCOME ASSESSMENT; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; URINE RETENTION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CANADA; EARLY DETECTION OF CANCER; EUROPE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84867544234     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.011428.x     Document Type: Review

References (28)

1. Globecan 2008. Prostate Cancer Incidence and Mortality Worldwide in 2008-Summary. Available at: http://globocan.iarc.fr/factsheets/cancers/prostate. asp. Accessed July 2012
2. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
3. Amercian Cancer Society. Prostate cancer. Available at: http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key- statistics. Accessed July 2012
4. Catalona WJ, Richie JP, Ahmann FR, et al,. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-90 (Pubitemid 24121936)
5. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
6. Catalona WJ, Smith DS, Ratliff TL, et al,. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
7. Bartsch G, Horninger W, Klocker H, et al,. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-24 (Pubitemid 32816361)
8. Oberaigner W, Siebert U, Horninger W, et al,. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 2012; 57: 57-62
9. Labrie F, Candas B, Cusan L, et al,. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-8 (Pubitemid 38509764)
10. Sandblom G, Varenhorst E, Lofman O, et al,. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004; 46: 717-23 (Pubitemid 39488400)
11. Kjellman A, Akre O, Norming U, et al,. 15-year follow-up of a population based prostate cancer screening study. J Urol 2009; 181: 1615-21
12. Andriole GL, Crawford ED, Grubb RL 3rd, et al,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
13. Grubb RL 3rd, Pinsky PF, Greenlee RT, et al,. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102: 1524-30
14. Schroder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
15. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ,. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 2011; 29: 464-7
16. Hugosson J, Carlsson S, Aus G, et al,. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32
17. Djulbegovic M, Beyth RJ, Neuberger MM, et al,. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543
18. Ilic D, O'Connor D, Green S, Wilt TJ,. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011; 107: 882-91
19. Chou R, Croswell JM, Dana T, et al,. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 762-71
20. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schröder FH,. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60: 826-30 (Pubitemid 35300348)
21. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ,. Infectious complications and hospital admissions after prostate biopsy in a European Randomized Trial. Eur Urol 2012; 61: 1110-4
22. Draisma G, Boer R, Otto SJ, et al,. Lead times and overdetection due to prostate specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78 (Pubitemid 36833878)
23. Roobol MJ, Steyerberg EW, Kranse R, et al,. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010; 57: 79-85
24. Thompson IM, Ankerst DP, Chi C, et al,. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 2005; 294: 66-70 (Pubitemid 41002840)
25. AUA. Prostate cancer: screening and management. Available at: http://www.auanet.org/content/education-and-meetings/med-stu-curriculum/ prostate-cancer-PSA.pdf. Accessed July 2012
26. Wolf AM, Wender RC, Etzioni RB, et al,. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70-98
27. Kawachi MH, Bahnson RR, Barry M, et al,. National Comprehensive Cancer Network clinical practice guidelines in oncology: prostate cancer early detection (v.2.2007). Available at: http://www.nccn.org/professionals/physician- gls/PDF/prostate-detection.pdf. Accessed July 2012
28. Heidenreich A, Bolla M, Joniau S, et al,. EAU Guidelines on Prostate cancer 2011. Available at: http://www.uroweb.org/gls/pdf/08-Prostate- Cancer%20September%2022nd%202011.pdf. Accessed July 2012